CO6251264A2 - Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k - Google Patents

Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k

Info

Publication number
CO6251264A2
CO6251264A2 CO09146663A CO09146663A CO6251264A2 CO 6251264 A2 CO6251264 A2 CO 6251264A2 CO 09146663 A CO09146663 A CO 09146663A CO 09146663 A CO09146663 A CO 09146663A CO 6251264 A2 CO6251264 A2 CO 6251264A2
Authority
CO
Colombia
Prior art keywords
ring
atom
independently selected
halogen
optionally substituted
Prior art date
Application number
CO09146663A
Other languages
English (en)
Inventor
Alexander Graham Dossetter
Nicola Murdoch Heron
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6251264A2 publication Critical patent/CO6251264A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

1.- Un compuesto de fórmula (I)donde: A es un anillo alifático de 5 a 7 miembros que contiene opcionalmente un doble enlace y que comprende opcionalmente un átomo de oxígeno como un miembro del anillo y que está opcionalmente sustituido por hasta tres sustituyentes cada uno de ellos seleccionado independientemente entre halógeno, C1-2alquilo y C3-4carbociclilo; R2 es hidrógeno o C1-6 alquilo; R1 y R2 junto con el átomo de nitrógeno al que están enlazados forman un anillo heterocíclico saturado o parcialmente insaturado de 5 a 7 miembros, dicho anillo comparte al menos un átomo con un segundo anillo monocíclico saturado, parcialmente insaturado o insaturado para formar un sistema de anillos bicíclico; dicho sistema de anillos bicíclico comparte al menos un átomo con un tercer anillo saturado, parcialmente insaturado o insaturado para formar un sistema de anillos tricíciclo que comprende hasta 19 átomos en los anillos, y donde el sistema de anillos tricíclico comprende opcionalmente hasta cinco heteroátomos cada uno de ellos seleccionado independientemente entre átomos de O, S o N, y está opcionalmente sustituido por hasta tres sustituyentes cada uno seleccionado independientemente entre fenilo, bencilo, naftilo, C1-6 alquilo, C2-6alquenilo, C2-6alquinilo, ciano, halógeno, COOR3, COR3, NO2, OR3, CONR4R5, NR4R5, C1-2alcansulfonil-, heteroarilo monocíclico que comprende hasta 7 átomos en el anillo y heteroarilo bicíclico que comprende hasta 12 átomos de carbono, y el sistema de anillos tricíclico está opcionalmente sustituido en átomos de carbono adyacentes por un grupo -O-C(R8)2-O-, en el que R8 es un átomo de hidrógeno o halógeno, para formar un grupo 1,3-dioxolo, y donde (i) además, fenilo, naftilo, C1-6 alquilo, C2-6alquenilo, C2-6alquinilo y bencilo están opcionalmente sustituidos por hasta tres sustituyentes cada uno seleccionado independientemente entre halógeno, NR4R5, SO2R3, ...
CO09146663A 2007-06-26 2009-12-22 Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k CO6251264A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94617807P 2007-06-26 2007-06-26
US4284008P 2008-04-07 2008-04-07

Publications (1)

Publication Number Publication Date
CO6251264A2 true CO6251264A2 (es) 2011-02-21

Family

ID=39761131

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09146663A CO6251264A2 (es) 2007-06-26 2009-12-22 Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k

Country Status (19)

Country Link
US (1) US8008279B2 (es)
EP (1) EP2170879B1 (es)
JP (1) JP2010531344A (es)
KR (1) KR20100039862A (es)
CN (1) CN101687864A (es)
AR (1) AR067156A1 (es)
AU (1) AU2008269513B2 (es)
BR (1) BRPI0813306A2 (es)
CA (1) CA2689945A1 (es)
CL (1) CL2008001899A1 (es)
CO (1) CO6251264A2 (es)
EC (1) ECSP109882A (es)
IL (1) IL202519A0 (es)
NZ (1) NZ581719A (es)
PE (1) PE20090841A1 (es)
RU (1) RU2470023C2 (es)
TW (1) TW200911806A (es)
UY (1) UY31180A1 (es)
WO (1) WO2009001129A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK1150388A1 (en) * 2008-01-25 2011-12-23 Medivation Technologies Inc New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof 2345--1h-[43-b]
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
JP2012504137A (ja) 2008-09-29 2012-02-16 アボット・ラボラトリーズ インドール誘導体およびインドリン誘導体ならびにそれらの使用方法
CA2745085C (en) * 2008-12-18 2018-03-06 Merck Patent Gmbh Tricyclic azaindoles
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
RS53130B (en) * 2009-10-21 2014-06-30 Boehringer Ingelheim International Gmbh INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
US8778959B2 (en) 2009-12-17 2014-07-15 Abbvie Inc. AZA-bridged ring-fused indoles and indolines
MX2012007031A (es) 2009-12-17 2012-07-04 Abbott Lab Indoles e indolinas fusionadas al anillo amina de cabeza de puente utiles para tratar transtornos neurodegenerativos y neuropsiquiatricos.
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
CA2827642A1 (en) 2011-02-18 2012-11-15 Medivation Technologies, Inc. Compounds and methods of treating diabetes
EP2802591B1 (en) * 2012-01-11 2016-03-16 F.Hoffmann-La Roche Ag Macrocyclic amides as protease inhibitors
CN103086923B (zh) * 2013-01-21 2014-04-23 吉林大学 肼腈类组织蛋白酶k抑制剂及其在治疗骨质疏松症方面的应用
CN105593230B (zh) * 2013-10-08 2018-07-06 默沙东公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
WO2016027285A2 (en) * 2014-08-22 2016-02-25 Alkem Laboratories Ltd. Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors
CN105837479B (zh) * 2016-04-05 2017-10-27 吉林大学 肼腈类组织蛋白酶k抑制剂及其在制备治疗骨关节炎药物中的应用
CA3058190A1 (en) * 2017-03-29 2018-10-04 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
WO2023138695A1 (zh) * 2022-01-21 2023-07-27 山东新时代药业有限公司 一种组织蛋白酶k抑制剂与其制备方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009110A1 (en) * 1999-07-30 2001-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Novel succinate derivative compounds useful as cysteine protease inhibitors
AU779855B2 (en) * 2000-01-06 2005-02-17 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
WO2001068645A2 (en) 2000-03-15 2001-09-20 Axys Pharmaceuticals, Inc. N-cyanomethylcarboxamides and their use as protease inhibitors
AU2002254099B2 (en) * 2001-03-02 2006-07-06 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
RU2278863C2 (ru) * 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
JP2005517640A (ja) * 2001-12-04 2005-06-16 エフ．ホフマン−ラ　ロシュ　アーゲー 置換２−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
JP4486505B2 (ja) 2002-12-19 2010-06-23 ブリストル−マイヤーズ スクイブ カンパニー セロトニン・レセプタ作用薬および拮抗薬としての置換トリ環式ガンマ−カルボリン化合物

Also Published As

Publication number Publication date
BRPI0813306A2 (pt) 2017-05-16
AU2008269513B2 (en) 2011-06-16
IL202519A0 (en) 2010-06-30
JP2010531344A (ja) 2010-09-24
EP2170879B1 (en) 2013-01-16
AU2008269513A1 (en) 2008-12-31
NZ581719A (en) 2011-08-26
AR067156A1 (es) 2009-09-30
ECSP109882A (es) 2010-02-26
RU2010101279A (ru) 2011-08-10
PE20090841A1 (es) 2009-08-02
CA2689945A1 (en) 2008-12-31
CL2008001899A1 (es) 2009-07-17
KR20100039862A (ko) 2010-04-16
EP2170879A1 (en) 2010-04-07
US20090012077A1 (en) 2009-01-08
US8008279B2 (en) 2011-08-30
WO2009001129A1 (en) 2008-12-31
RU2470023C2 (ru) 2012-12-20
WO2009001129A9 (en) 2010-02-04
TW200911806A (en) 2009-03-16
UY31180A1 (es) 2009-01-30
CN101687864A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
CO6251264A2 (es) Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k
NI202000072A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR075243A1 (es) Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
AR061867A1 (es) Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa
AR060590A1 (es) Compuestos imidazo
AR074002A1 (es) Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir)
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
ECSP11011185A (es) Compuestos orgánicos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
ECSP099803A (es) Derivados de bencimidazol
AR061603A1 (es) Derivados de etenilcarboxamidas microbicidas
AR056645A1 (es) Compuestos de urea sustituida inhibidores de enzimas chk1 .
ECSP088149A (es) 3-acilaminobenzanilidas insecticidas
AR056888A1 (es) Derivados de heterociclil imidazol
PE20061362A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion
ES2409404T3 (es) Compuestos heterocíclicos de fenoximetilo

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed